View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 13, 2020updated 12 Jul 2022 11:48am

US researchers evaluate antidepressant fluvoxamine for Covid-19

Researchers from the Washington University School of Medicine in St Louis, Missouri, US are conducting a clinical trial to evaluate an antidepressant drug fluvoxamine to potentially treat Covid-19.

Researchers from the Washington University School of Medicine in St Louis, Missouri, US are conducting a clinical trial to evaluate an antidepressant drug fluvoxamine to potentially treat Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial comes after researchers at the University of Virginia (UVA) School of Medicine found that the drug may prevent overreactions by the immune system called cytokine storms, which could result in life-threatening organ failure.

Last year, the UVA researchers discovered that fluvoxamine may prevent sepsis, a deadly inflammatory disease characterised by overactive immune response. The drug was observed to decrease the generation of cytokines.

The drug showed effectiveness as a preventive sepsis therapy when tested in mice, according the researchers.

UVA neuroscience department researcher Alban Gaultier said: “If proven effective in decreasing the symptoms of Covid-19, this treatment would be a safe and affordable option for fighting the pandemic.

“Further, this approach could also be applied to other inflammatory conditions driven by cytokine storms, such as sepsis.”

The Covid-19 trial by the Washington University School of Medicine in St Louis will enrol 152 patients in Illinois and Missouri. Participants will be given fluvoxamine or a placebo during at-home quarantine.

Patients will also be supplied with thermometers, fingertip oxygen sensors, and automatic blood pressure monitors to self-report vital signs to the research team daily via phone calls or online.

Washington University researcher Eric Lenze said: “Using a psychiatric drug to treat Covid-19 may sound counterintuitive, but it’s no more counterintuitive than using a malaria drug.

“This drug has been around for decades, so we know how to use it safely. If effective, it could be an ideal drug to repurpose for outpatients with Covid.”

Even if the drug is ineffective against Covid-19, researchers expect participants to benefit from close supervision by doctors.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena